Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
Regeneron’s fianlimab lung test approaches
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
PD-1 drugs set to have their stomach cancer wings clipped
A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.
ESMO 2024 – Regeneron's fianlimab do-over
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
